PD09-04 INTERIM ANALYSIS OF A PHASE I SINGLE-ARM STUDY OF THE COMBINATION OF DURVALUMAB (MEDI4736) AND VICINIUM (OPORTUZUMAB MONATOX, VB4-845) IN SUBJECTS WITH HIGH-GRADE NON-MUSCLE-INVASIVE BLADDER CANCER PREVIOUSLY TREATED WITH BACILLUS CALMETTE-GUERIN (BCG) (NCT03258593)

Sandeep Gurram,Sonia Bellfield,Rebecca Dolan,Beatriz A. Walter,María Merino,Scot A. Niglio,Andrea Apolo Bethesda,Piyush K. Agarwal,Vladimir Valera

PD09-04 INTERIM ANALYSIS OF A PHASE I SINGLE-ARM STUDY OF THE COMBINATION OF DURVALUMAB (MEDI4736) AND VICINIUM (OPORTUZUMAB MONATOX, VB4-845) IN SUBJECTS WITH HIGH-GRADE NON-MUSCLE-INVASIVE BLADDER CANCER PREVIOUSLY TREATED WITH BACILLUS CALMETTE-GUERIN (BCG) (NCT03258593)

2021

Sandeep Gurram
Sonia Bellfield
Rebecca Dolan
Beatriz A. Walter
María Merino
Scot A. Niglio
Andrea Apolo Bethesda
Piyush K. Agarwal
Vladimir Valera

INTRODUCTION AND OBJECTIVE:Radical cystectomy is the gold standard treatment for high-risk, non-muscle invasive invasive bladder cancer (NMIBC) that fails to respond to intravesical treatment with ...

Keywords:

Durvalumab
non muscle invasive
Bladder cancer
Medicine
Gold standard (test)
Cystectomy
Urology
Interim analysis
previously treated
Single Arm Study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations